-
Article
Open AccessFinal analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in newly diagnosed multiple...
-
Article
Open AccessBuilding Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview
Review building of programs to eliminate Toxoplasma infections.
-
Article
Open AccessProspective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) has a favorable prognosis which has led to efforts to de-intensify treatment. Response-adaptive de-escalated treatment is promising, however imp...
-
Article
Open AccessHousehold air pollution, ultrasound measurement, fetal biometric parameters and intrauterine growth restriction
Low birthweight, intrauterine growth restriction (IUGR) and perinatal mortality have been associated with air pollution. However, intervention studies that use ultrasound measurements to assess the effects of ...
-
Article
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis.
-
Article
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia
Background We hypothesized that targeting two mechanisms of epigenetic silencing would be additive or synergistic with regard to expression of specific target genes. The primary objective of the ...
-
Article
Open AccessA randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
CEA is expressed in >90% of pancreatic cancers (PC) and may be an appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass toleran...
-
Article
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
Background Src kinases are activated in melanoma, and inhibition of Src kinase activity has pre-clinical anti-tumor effects. Targeting this pathway could therefore have therapeutic activity in pa...
-
Article
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
Irinotecan and thalidomide are commonly administered antineoplastic drugs. Combination treatment may potentiate their antitumor effect and protect against irinotecan’s intestinal toxicity. We investigated whet...
-
Article
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Purpose: Bryostatin-1 is a PKC modulator with direct anti-tumor activity and immunomodulatory properties. We combined different doses of Bryostatin-1 with IL-2 to determine effects on cli...
-
Article
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine
Modulation of platinating agent cytotoxicity has important clinical implications as a result of their widespread use in the treatment of many different cancers. O6-Benzylguanine (BG) enhances the cytotoxicity of ...
-
Article
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administratio...
-
Article
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors
E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immo...
-
Chapter
Methyl Transferase Activity in Secondary Leukemia
During a typical course of treatment for Hodgkin’s disease or non-Hodgkin’s lymphoma with MOPP, individuals receive approximately 1400 mg/m2 of procarbazine over a period of 14 days (DeVita et al., 1970). Procarb...
-
Chapter
Heterogeneity in the O6 Alkylguanine DNA Alkyltransferase (AGT) Activity of Human Peripheral Blood Lymphocytes (PBL’s)
The nature of the mechanisms controlling the protein content of mammalian cells and tissues is a central problem of modern biology. Recent studies on the structure of genes and their control elements in eukary...
